Khavinson Bioregulators

Khavinson tetrapeptide bioregulator (Ala-Glu-Asp-Leu) targeting bronchial and airway tissue. Developed at the St. Petersburg Institute of Bioregulation and Gerontology. Animal studies report bronchial epithelium effects. No Western clinical trials.

Synthetic Ala-Glu-Asp-Arg tetrapeptide developed by the Khavinson group as the cardiac Cytogen. Sequence is well-defined (AEDR, ~489.5 Da), but human trial evidence is Russian-institution dominated.

Synthetic Ala-Glu-Asp tripeptide derived from type XI collagen alpha-1 chain. Khavinson cartilage Cytogen with reported chondrocyte proliferation effects in cell culture.

Khavinson brain Cytomax peptide complex extracted from young calf brain tissue. Marketed for CNS support in cognitive aging and post-stroke recovery.

Khavinson bronchial Cytomax peptide complex extracted from young calf bronchial epithelium. Marketed for respiratory tract support. Russian-network clinical observation data only.

Synthetic Ala-Glu-Asp-Pro tetrapeptide derived by epitope mapping from Cortexin brain extract. Khavinson cortex Cytogen targeting central nervous system gene expression.

Synthetic Glu-Asp-Pro tripeptide identified by epitope mapping as a principal active component of Thymalin. Marketed as immune Cytogen in the Khavinson system.

Khavinson pineal Cytomax peptide complex extracted from young calf pineal gland. Marketed for circadian rhythm, sleep, and longevity. Russian-network clinical observation data only.

Synthetic tetrapeptide developed by Vladimir Khavinson; telomerase activation claims rest on Khavinson-group rodent studies and small Russian observational reports.

Khavinson adrenal Cytomax peptide complex extracted from young calf adrenal tissue. Marketed for adrenal support. No FDA approval, evidence is Russian-network dominated.

Synthetic Lys-Glu-Asp-Ala tetrapeptide developed as the Khavinson liver and immune Cytogen. Documented chromatin decondensation effects in cell culture.

Synthetic Glu-Asp-Leu tripeptide developed by the Khavinson group as a liver and GI cytogen. Sequence is well-defined (PubChem 444128), but human trial evidence is dominated by Russian-institution publications.

Synthetic Lys-Glu-Asp-Trp tetrapeptide developed by the Khavinson group as the pancreas Cytogen. Russian-network clinical observation data on glycemic markers; no independent Western RCT.

Khavinson tripeptide bioregulator (Glu-Asp-Arg) developed at the St. Petersburg Institute of Bioregulation and Gerontology. Brain-tissue-specific cytogen. Animal studies report neuroprotection and cognitive effects. No Western clinical trials.

Synthetic Lys-Glu-Asp-Pro tetrapeptide developed by the Khavinson group as the prostate Cytogen. Russian-network clinical observation data exists; no independent Western RCT, no FDA approval.

Khavinson cytomax (A-1) pancreas peptide bioregulator. 10 mg natural peptide complex extracted from calf pancreas under 12 months. Russian dietary supplement marketed for pancreatic function, digestion, and glucose metabolism support. No FDA approval.

Khavinson cytomax (A-7) liver peptide bioregulator. Natural peptide complex extracted from calf liver. Russian dietary supplement marketed for liver function support. Synthetic cytogen counterpart is Ovagen. No FDA approval, no Western clinical trials.

Khavinson tetrapeptide bioregulator (Lys-Glu-Asp-Gly) targeting testicular tissue. Proposed to support Leydig cell function and endogenous testosterone biosynthesis. Sold in Russia as dietary supplement. No FDA approval, no Western clinical trials.

Khavinson testicular Cytomax peptide complex extracted from young calf testis. Marketed for testosterone-axis and reproductive support. Russian-network clinical observation data only.

Polypeptide complex extracted from calf thymus. The foundational Khavinson cytomedin developed at the Military Medical Academy St. Petersburg. Approved in Russia as immunomodulator since 1982. 6-8 year elderly study with Epithalamin showed mortality reduction. No FDA approval.

Synthetic dipeptide (L-Glu-L-Trp) isolated from Thymalin as its principal active component. Russian-approved pharmaceutical since 1990 in three formulations (IM injection, nasal spray, topical cream). Used clinically for immunomodulation. No FDA approval.

Khavinson vascular Cytomax extracted from young calf aortic tissue. Contains a complex of peptides up to ~10 kDa. Marketed for vessel function. No Western RCT, no FDA approval, evidence base is Russian-institution dominated.

Synthetic Glu-Asp dipeptide developed by the Khavinson group as a bladder cytogen. Evidence is dominated by Russian-institution publications. No FDA approval, no Western RCT, no peer-reviewed pharmacokinetic data.

Khavinson tripeptide bioregulator (Lys-Glu-Asp) targeting vascular endothelium. Developed at the St. Petersburg Institute of Bioregulation and Gerontology. Russian preclinical research only. No Western clinical trials. Available as supplement in Russia.

Khavinson dipeptide bioregulator (Lys-Glu) targeting thymus and immune system. Developed at the St. Petersburg Institute of Bioregulation and Gerontology. Animal studies report immune restoration in aged animals and lifespan extension. No Western clinical trials.

Khavinson female reproductive Cytomax peptide complex extracted from young calf ovarian tissue. Marketed for female reproductive support and menopausal symptoms.